ReviewCells2024
Eosinophilic Asthma: Pathophysiology and Therapeutic Horizons.
Review in Cells, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.
- Efficacy and safety of Depemokimab in asthma with eosinophilic phenotype: a systematic review and meta-analysis of randomized controlled trials.BMC immunology · 2025Pooled it
- The efficacy and safety of omalizumab in the treatment of asthma: an overview of systematic reviews and meta analyses.Frontiers in medicine · 2025Pooled it
- A Single Dose, Randomized, Open-Label, Cross-Over Bioequivalence Study of Budesonide Pressurized Metered-Dose Inhaler in Healthy Chinese Subjects.Pharmacology research & perspectives · 2025Trial
- Relationship between serum albumin and blood eosinophils in adolescents with allergic triad: A Cross-sectional study from NHANES.Medicine · 2026Article
- Small airway dysfunction as a functional barrier to spirometry-defined clinical remission in severe asthma treated with biologic therapies.The World Allergy Organization journal · 2026Article
- Restoring the Airway Barrier: How Targeting Eosinophilic Inflammation Shapes Epithelial Health and Clinical Remission in Asthma.Diagnostics (Basel, Switzerland) · 2026Review
- Emerging Targeted Therapies in Asthma: From Upstream Epithelial Biology to Novel Biologic and Small-Molecule Strategies.Tuberculosis and respiratory diseases · 2026Review
- Structure and function of therapeutic antibodies approved by the US FDA in 2025.Antibody therapeutics · 2026Review
- Nasal Cytology as a Local Biomarker of Airway Inflammation: A Paradigm Shift in Precision Medicine.Pathophysiology : the official journal of the International Society for Pathophysiology · 2026Article
- Nanozymes as Emerging Therapeutics for Asthma: A Redox-Responsive and Immunomodulatory Strategy.Biomedicines · 2026Review
- Protective effect ofVeterinarni medicina · 2026Article
- Investigating the therapeutic potential of polymeric roflumilast nanosuspension in modulating asthma hallmarks using an in vivo ovalbumin model.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Regulation of mCell biology and toxicology · 2026Review
- Ameliorating Effects ofAntioxidants (Basel, Switzerland) · 2026Article
- Review
- Real-World Effectiveness Following Benralizumab Use in Patients with Severe Eosinophilic Asthma in Romania: A Retrospective Cohort Study (BREEZE).Journal of clinical medicine · 2026Article
- Phenotyping moderate asthma earlier by analyzing induced sputum eosinophils, blood eosinophils, and atopy: a cross-sectional comparison with severe asthma.Respiratory research & clinical practice · 2026Article
- Pulsed 980 nm near-infrared photobiomodulation attenuates OVA-induced allergic asthma by modulating Th2 cytokine responses and inflammatory cell infiltration.Scientific reports · 2025Article
- Novel insights into asthma pathophysiology and pharmacological interventions: spiral of respiratory symptoms and psychiatric episodes.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Review
- CPA3 drives the development of asthma by promoting the activation of the JAK/STAT6 pathway.Respiratory research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Asthma is a prevalent chronic non-communicable disease, affecting approximately 300 million people worldwide. It is characterized by significant airway inflammation, hyperresponsiveness, obstruction, and remodeling. Eosinophilic asthma, a subtype of asthma, involves the accumulation of eosinophils in the airways. These eosinophils release mediators and cytokines, contributing to severe airway inflammation and tissue damage. Emerging evidence suggests that targeting eosinophils could reduce airway remodeling and slow the progression of asthma. To achieve this, it is essential to understand the immunopathology of asthma, identify specific eosinophil-associated biomarkers, and categorize patients more accurately based on the clinical characteristics (phenotypes) and underlying pathobiological mechanisms (endotypes). This review delves into the role of eosinophils in exacerbating severe asthma, exploring various phenotypes and endotypes, as well as biomarkers. It also examines the current and emerging biological agents that target eosinophils in eosinophilic asthma. By focusing on these aspects, both researchers and clinicians can advance the development of targeted therapies to combat eosinophilic pathology in severe asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.